Discover the full record of transactions filed by Laurence BOIRON, Représentante permanente de Boiron Développement au Conseil d’administration de Boiron SA. Officer active across 1 companies, notably BOIRON. In total, 2 disclosures have been logged. Total volume traded: €34.3m. The latest transaction was filed on 20 October 2023 — Cession. Regulator: AMF. All data is free.
2 of 2 declarations
Laurence Boiron holds a governance role within the Boiron group as the permanent representative of Boiron Développement on the Board of Directors of Boiron SA. In that capacity, she participates in strategic oversight, long-term supervision and the governance of one of France’s best-known listed healthcare groups. Boiron is historically rooted in a family shareholding structure, and her role reflects the continuity of that ownership model within a listed-company framework. Her position is primarily one of corporate governance rather than day-to-day executive management. It places her at the center of key board-level topics such as strategy, financial discipline, risk supervision, compliance and the preservation of the group’s long-term interests. Boiron operates in a highly regulated environment, with strong expectations around industrial quality, pharmaceutical compliance, public reputation and stakeholder relations. A board representative in this context must combine an understanding of corporate structure with sensitivity to market, legal and reputational issues. Through Boiron Développement, Laurence Boiron is connected to the family shareholder base that has long shaped the company’s identity and strategic continuity. Her role therefore carries particular importance in the balance between family ownership, listed-company governance and operational execution. It also positions her within discussions on international development, industrial organization, distribution, shareholder alignment and the group’s ability to adapt to changes in regulation and market perception. More broadly, Laurence Boiron represents the continuity of a family-led governance tradition in a company where stability of capital and strategic consistency are major assets. Her presence on the board supports the oversight of the group’s transformation, financial performance and long-term positioning in the healthcare sector. For investors, business partners and executive-search audiences, she is best understood as a governance figure associated with the stewardship and continuity of the Boiron group.